Trial Profile
A Double-blind, Placebo-controlled, Randomized, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Japanese Subjects and An Open-label, Single Dose Study to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 19 Aug 2019
Price :
$35
*
At a glance
- Drugs Efinopegdutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Pharmaceutical KK
- 14 Aug 2019 Status changed from recruiting to discontinued.
- 17 Oct 2018 Planned End Date changed from 16 Sep 2019 to 3 Jul 2019.
- 17 Oct 2018 Planned primary completion date changed from 16 Sep 2019 to 3 Jul 2019.